Episode Summary
Executive Summary: The conversation argues that embryo selection via IVF is not gene editing but information-based choice using polygenic risk scores. The guest defends it as a way to reduce disease and modestly improve traits like intelligence, while rejecting fears of eugenics when decisions remain voluntary. The debate centers on ethics, personhood, inequality, validation, ancestry bias, and how genetics may change family planning and social norms.
Main Topics: Embryo selection vs. gene editing (Priority: 5/5): The guest distinguishes embryo selection from altering genes, emphasizing that the technology only reveals existing genetic variation and helps parents choose among embryos already created through IVF. Disease prevention and trait selection (Priority: 5/5): A major theme is the difference between screening to avoid serious disease and screening for traits like intelligence, with the guest arguing both are morally similar if they improve prospects and reduce suffering. Eugenics, autonomy, and government coercion (Priority: 5/5): The guest argues the real ethical line is between voluntary individual choice and coercive state control, warning that subsidies or mandates could move the practice toward coercive eugenics. Validation, scientific rigor, and ancestry bias (Priority: 5/5): The discussion explains how polygenic scores are built and validated, stressing sibling/within-family studies and the importance of measuring performance across ancestry groups to avoid misleading results. Personhood, non-identity, and moral culpability (Priority: 4/5): The conversation explores whether selecting embryos changes who exists rather than merely improving outcomes, drawing on Parfit-style non-identity arguments and wrongful-life thought experiments. Social stigma, compassion, and changing norms (Priority: 4/5): The guest claims genetic explanation should reduce stigma by replacing blame with understanding, while acknowledging that selection may create new cultural expectations and buyer’s remorse. Global competition and policy divergence (Priority: 4/5): The episode forecasts that countries with more permissive attitudes toward genetics and IVF may accelerate adoption, pushing Europe and the US to adapt as the technology becomes harder to restrict.
Key Arguments: Embryo selection is not gene editing; it only uses existing genetic information from embryos produced in IVF. Parents already select embryos visually based on morphology, so polygenic screening is a more informed version of a current practice. Public resistance often comes from post-WWII taboos about intelligence and mental traits, not from a principled difference between disease and enhancement. The main ethical danger is government coercion or mandated coverage, not private choice by informed parents. Genetic inequality may increase somewhat, but embryo selection produces modest gains rather than dramatic class stratification in the short term. Consumers should demand transparency: score construction, validation methods, and ancestry performance before trusting any company. Most pleiotropy appears positive, suggesting that selecting against one disorder may reduce other risks as well. Understanding genetics should increase compassion and reduce moral blame for conditions like schizophrenia or depression. Some traits should not be selected for, especially antisocial traits like psychopathy or sadism, even if laws may be unnecessary if norms are strong. Polygenic scores can be validated using large biobanks and sibling comparisons, and the key test is whether predictions hold within families and across ancestry groups.
Data Points: IVF birth prevalence in the US: about 1 in 3% - Guest estimates the share of US births via IVF, contrasting it with Denmark's much higher usage. IVF birth prevalence in Denmark: 10% - Used to show IVF is already common in some countries. Public support for embryo screening for disease: 70-75% of Americans - Cited as survey support for selecting embryos to avoid disease. Public support for embryo screening for intelligence: about 40% of Americans - Shows a large acceptance gap versus disease screening. Polygenic score loss in African ancestry samples: up to 80% accuracy loss - Discussed as a known problem for scores trained mainly on European data. Embryos used in simulation reports: 500 simulations - Parents receive a simulated distribution of embryo outcomes based on repeated recombination of parental DNA. Intelligence spread across 10 embryos: about 15.5 IQ points - Guest claims embryo selection can reveal a meaningful spread among embryos. Real spread between 10 embryos: about 31-32 IQ points - Used to argue selection can capture roughly half the variance. Breast cancer caused by BRCA variants: about 3% of cases - Illustrates that even famous monogenic-ish risk factors explain only a minority of cases. Customer count mentioned: about 80 customers - Early stealth-phase adoption figure for the company. Future goal mentioned: thousands in the coming year - Claim about expected near-term growth after coming out of stealth. Age of star scientist mentioned: 36 - Alex Strudwick Young’s age at cancer diagnosis, used in a treatment-autonomy example.
Pivotal Quotes: "All we're doing is revealing more information about the natural genetic variation that exists in your embryos and letting you choose which one to implant." — Guest: Core definition of embryo selection, distinguishing it from gene editing. "The real question is, why?" — Guest: Challenges doctors’ reluctance to allow polygenic selection when they already permit monogenic screening. "It turns out like selecting for IQ is not just a thing you do selfishly to have smart kids, it makes them more likely to live longer, healthier lives, makes them more likely to be cooperative." — Guest: Summarizes the claimed broader benefits of intelligence selection.
Implications: If the guest is right, embryo selection will normalize as a fertility tool, pushing medicine toward transparent probabilistic genetics, more personalized reproductive choice, and sharper fights over inequality, stigma, and regulation.
About Modern Wisdom
Chris Williamson in long-form conversation with the world's most interesting people - psychologists, scientists, authors, comedians and entrepreneurs - on life, science, health, fitness, business and philosophy.